197 related articles for article (PubMed ID: 27837030)
21. Prognostic Factors for Luminal B-like Breast Cancer.
Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
[TBL] [Abstract][Full Text] [Related]
22. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
[TBL] [Abstract][Full Text] [Related]
23. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
24. Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers.
Abdel-Fatah T; Arora A; Agarwal D; Moseley P; Perry C; Thompson N; Green AR; Rakha E; Chan S; Ball G; Ellis IO; Madhusudan S
Breast Cancer Res Treat; 2014 Jul; 146(2):309-20. PubMed ID: 24972688
[TBL] [Abstract][Full Text] [Related]
25. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.
Xu H; Yan M; Patra J; Natrajan R; Yan Y; Swagemakers S; Tomaszewski JM; Verschoor S; Millar EK; van der Spek P; Reis-Filho JS; Ramsay RG; O'Toole SA; McNeil CM; Sutherland RL; McKay MJ; Fox SB
Breast Cancer Res; 2011 Jan; 13(1):R9. PubMed ID: 21255398
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
[No Abstract] [Full Text] [Related]
27. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S
Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786
[TBL] [Abstract][Full Text] [Related]
28. Genome-Wide Analysis Unveils DNA Helicase RECQ1 as a Regulator of Estrogen Response Pathway in Breast Cancer Cells.
Lu X; Redon CE; Tang W; Parvathaneni S; Bokhari B; Debnath S; Li XL; Muys BR; Song Y; Pongor LS; Sheikh O; Green AR; Madhusudan S; Lal A; Ambs S; Khan J; Aladjem MI; Sharma S
Mol Cell Biol; 2021 Mar; 41(4):. PubMed ID: 33468559
[TBL] [Abstract][Full Text] [Related]
29. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
30. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
[TBL] [Abstract][Full Text] [Related]
31. Tumor characteristics and prognosis in familial breast cancer.
Arpino G; Pensabene M; Condello C; Ruocco R; Cerillo I; Lauria R; Forestieri V; Giuliano M; De Angelis C; Montella M; Crispo A; De Placido S
BMC Cancer; 2016 Nov; 16(1):924. PubMed ID: 27899083
[TBL] [Abstract][Full Text] [Related]
32. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
[TBL] [Abstract][Full Text] [Related]
33. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.
Sieuwerts AM; Willis S; Burns MB; Look MP; Meijer-Van Gelder ME; Schlicker A; Heideman MR; Jacobs H; Wessels L; Leyland-Jones B; Gray KP; Foekens JA; Harris RS; Martens JW
Horm Cancer; 2014 Dec; 5(6):405-13. PubMed ID: 25123150
[TBL] [Abstract][Full Text] [Related]
34. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795
[TBL] [Abstract][Full Text] [Related]
35. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
Karn T; Ruckhäberle E; Hanker L; Müller V; Schmidt M; Solbach C; Gätje R; Gehrmann M; Holtrich U; Kaufmann M; Rody A
Breast Cancer Res Treat; 2011 Nov; 130(2):409-20. PubMed ID: 21203899
[TBL] [Abstract][Full Text] [Related]
37. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
[TBL] [Abstract][Full Text] [Related]
38. Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.
Shamanna RA; Lu H; Croteau DL; Arora A; Agarwal D; Ball G; Aleskandarany MA; Ellis IO; Pommier Y; Madhusudan S; Bohr VA
Oncotarget; 2016 Mar; 7(12):13269-84. PubMed ID: 26959889
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
40. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
